Author of

• 14409

  +

  P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Localized Disease - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14439

    +

    P2.02-030 - Bronchoscopic Therapy for Centrally-Located Early Lung Cancers (ID 2541)

    09:30 - 17:00  |  Author(s): T. Ibi
    • Abstract
    • Slides

    Background:
    Photodynamic therapy (PDT) is recommended as a treatment option for centrally-located early lung cancers (CLELCs). Although PDT using Photofrin has not been recommended for large tumors or deeply invasive tumors, in the past, if their mass is reduced by electrocautery, PDT with the NPe6 second-generation photosensitizer has been found to be capable of destroying the residual cancer lesion. NPe6 is a second-generation photosensitizer, and since it has a longer absorption band (664 nm) than Photofrin (630 nm), we hypothesized that NPe6-PDT would exert a strong antitumor effect against cancer lesions greater than > 1.0 cm in diameter.
    
    Methods:
    Between June 2004 and October 2013, 128 patients (151 lesions) with CLELC underwent NPe6-PDT after the extent of their tumors had been assessed by fluorescence bronchoscopy for photodynamic diagnosis and tumor depth had been assessed by OCT.
    
    Results:
    Ninety-four cancer lesions ≦1.0 cm in diameter and 57 lesions >1.0 cm in diameter were identified, and the CR rate was 93.6% (88/94) and 96.5% (55/57), respectively. After the mass of large tumors and deeply invasive tumors, had been reduced by electrocautery, NPe6-PDT was capable of destroying the residual cancer lesions.
    
    Conclusion:
    NPe6-PDT has a strong antitumor effect against CLELCs >1.0 cm in diameter, thereby enabling the destruction of residual cancer lesions after mass reduction of large nodular or polypoid type-lung cancers by electrocautery. The PDT guidelines for lung cancers should therefore be revised, because use of NPe6-PDT will enable expansion of the clinical indications for PDT.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.